Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA. Zhang J, et al. Among authors: van der gang lf. J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641-8. doi: 10.1016/j.jaad.2024.04.026. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38653344
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT, Politiek K, Van der Gang LF, De Graaf M, De Bruin-Weller MS, Schuttelaar MLA. Kamphuis E, et al. Among authors: van der gang lf. Acta Derm Venereol. 2024 Feb 7;104:adv19454. doi: 10.2340/actadv.v104.19454. Acta Derm Venereol. 2024. PMID: 38323500 Free PMC article.
Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Musters AH, van Lookeren FL, van der Gang LF, Middelkamp-Hup MA, Bosma AL, Jessurun NT, Lapeere H, Nguyen AL, Ouwerkerk W, de Schepper S, Gerbens LAA, Spuls PI. Musters AH, et al. Among authors: van der gang lf. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):530-542. doi: 10.1111/jdv.19643. Epub 2023 Nov 29. J Eur Acad Dermatol Venereol. 2024. PMID: 38031478
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis.
Boesjes CM, van der Gang LF, Bakker DS, Ten Cate TA, Spekhorst LS, de Graaf M, van Dijk MR, de Bruin-Weller MS. Boesjes CM, et al. Among authors: van der gang lf. JAMA Dermatol. 2023 Nov 1;159(11):1240-1247. doi: 10.1001/jamadermatol.2023.3849. JAMA Dermatol. 2023. PMID: 37851456
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Boesjes CM, Van der Gang LF, Zuithoff NPA, Bakker DS, Spekhorst LS, Haeck I, Kamsteeg M, De Graaf M, De Bruin-Weller MS. Boesjes CM, et al. Among authors: van der gang lf. Acta Derm Venereol. 2023 Feb 16;103:adv00872. doi: 10.2340/actadv.v103.5243. Acta Derm Venereol. 2023. PMID: 36794894 Free PMC article.